James M Burns Jr

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5473470/publications.pdf

Version: 2024-02-01

933447 1125743 17 240 10 13 citations g-index h-index papers 17 17 17 327 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Inclusion of an Optimized Plasmodium falciparum Merozoite Surface Protein 2–Based Antigen in a Trivalent, Multistage Malaria Vaccine. Journal of Immunology, 2021, 206, 1817-1831.	0.8	2
2	Maintaining immunogenicity of blood stage and sexual stage subunit malaria vaccines when formulated in combination. PLoS ONE, 2020, 15, e0232355.	2,5	3
3	Title is missing!. , 2020, 15, e0232355.		O
4	Title is missing!. , 2020, 15, e0232355.		0
5	Title is missing!. , 2020, 15, e0232355.		O
6	Title is missing!. , 2020, 15, e0232355.		0
7	Immunization with merozoite surface protein 2 fused to a Plasmodium-specific carrier protein elicits strain-specific and strain-transcending, opsonizing antibody. Scientific Reports, 2019, 9, 9022.	3.3	12
8	Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of Recombinant <i>Pf</i> s25, a Leading Transmission-Blocking Vaccine Candidate. Infection and Immunity, 2018, 86, .	2.2	15
9	A step forward for an attenuated blood-stage malaria vaccine. BMC Medicine, 2018, 16, 204.	5.5	4
10	Na+ Influx Induced by New Antimalarials Causes Rapid Alterations in the Cholesterol Content and Morphology of Plasmodium falciparum. PLoS Pathogens, 2016, 12, e1005647.	4.7	40
11	Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys. Malaria Journal, 2016, 15, 159.	2.3	16
12	A Chimeric Plasmodium falciparum Merozoite Surface Protein Vaccine Induces High Titers of Parasite Growth Inhibitory Antibodies. Infection and Immunity, 2013, 81, 3843-3854.	2.2	23
13	Evaluation of the Immunogenicity and Vaccine Potential of Recombinant Plasmodium falciparum Merozoite Surface Protein 8. Infection and Immunity, 2012, 80, 2473-2484.	2.2	16
14	Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection. Vaccine, 2010, 28, 6876-6884.	3.8	16
15	Enhanced Protection against Malaria by a Chimeric Merozoite Surface Protein Vaccine. Infection and Immunity, 2007, 75, 1349-1358.	2.2	38
16	Protection against Plasmodium chabaudi Malaria Induced by Immunization with Apical Membrane Antigen 1 and Merozoite Surface Protein 1 in the Absence of Gamma Interferon or Interleukin-4. Infection and Immunity, 2004, 72, 5605-5612.	2.2	29
17	Immunization against Plasmodium chabaudi malaria using combined formulations of apical membrane antigen-1 and merozoite surface protein-1. Vaccine, 2003, 21, 1843-1852.	3.8	26